Town & Country Bank & Trust CO dba First Bankers Trust CO grew its holdings in AbbVie Inc (NYSE:ABBV) by 102.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 86,734 shares of the company’s stock after purchasing an additional 43,992 shares during the period. AbbVie comprises approximately 2.1% of Town & Country Bank & Trust CO dba First Bankers Trust CO’s investment portfolio, making the stock its 13th biggest holding. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in AbbVie were worth $7,996,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Pure Financial Advisors Inc. boosted its position in AbbVie by 1.0% during the fourth quarter. Pure Financial Advisors Inc. now owns 11,606 shares of the company’s stock worth $1,070,000 after purchasing an additional 116 shares during the period. Planning Directions Inc. boosted its position in shares of AbbVie by 3.3% in the fourth quarter. Planning Directions Inc. now owns 3,890 shares of the company’s stock valued at $359,000 after acquiring an additional 126 shares during the period. IMS Capital Management boosted its position in shares of AbbVie by 1.0% in the third quarter. IMS Capital Management now owns 14,797 shares of the company’s stock valued at $1,400,000 after acquiring an additional 143 shares during the period. First National Bank Sioux Falls boosted its position in shares of AbbVie by 3.6% in the fourth quarter. First National Bank Sioux Falls now owns 4,213 shares of the company’s stock valued at $388,000 after acquiring an additional 145 shares during the period. Finally, Avitas Wealth Management LLC boosted its position in shares of AbbVie by 0.9% in the third quarter. Avitas Wealth Management LLC now owns 16,717 shares of the company’s stock valued at $1,581,000 after acquiring an additional 150 shares during the period. Institutional investors own 70.63% of the company’s stock.
In other news, EVP Henry O. Gosebruch sold 42,450 shares of the company’s stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $90.10, for a total value of $3,824,745.00. Following the completion of the transaction, the executive vice president now owns 30,350 shares of the company’s stock, valued at $2,734,535. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Vice Chairman Laura J. Schumacher sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, December 28th. The shares were sold at an average price of $90.00, for a total value of $2,250,000.00. The disclosure for this sale can be found here. Insiders sold 263,440 shares of company stock valued at $24,029,804 in the last ninety days. 0.07% of the stock is currently owned by insiders.
NYSE ABBV traded down $0.41 during trading on Monday, hitting $79.26. 549,734 shares of the company’s stock were exchanged, compared to its average volume of 8,067,862. The company has a market cap of $119.84 billion, a price-to-earnings ratio of 10.02, a PEG ratio of 1.20 and a beta of 1.17. AbbVie Inc has a fifty-two week low of $75.77 and a fifty-two week high of $122.00.
AbbVie (NYSE:ABBV) last issued its earnings results on Friday, January 25th. The company reported $1.90 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.92 by ($0.02). The business had revenue of $8.31 billion for the quarter, compared to analyst estimates of $8.37 billion. AbbVie had a negative return on equity of 1,343.27% and a net margin of 17.36%. The firm’s revenue was up 7.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.48 EPS. As a group, equities research analysts forecast that AbbVie Inc will post 8.69 EPS for the current year.
AbbVie declared that its board has initiated a stock buyback plan on Thursday, December 13th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the company to buy up to 3.8% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.
A number of brokerages have recently issued reports on ABBV. Zacks Investment Research raised shares of AbbVie from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a research report on Tuesday, January 8th. Credit Suisse Group set a $79.00 target price on shares of AbbVie and gave the company a “hold” rating in a research report on Friday, January 25th. BMO Capital Markets reduced their target price on shares of AbbVie from $78.00 to $71.00 and set an “underperform” rating for the company in a research report on Monday, November 5th. ValuEngine raised shares of AbbVie from a “sell” rating to a “hold” rating in a research report on Monday, November 12th. Finally, Argus reduced their target price on shares of AbbVie from $130.00 to $115.00 and set a “buy” rating for the company in a research report on Tuesday, November 6th. Five equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $96.85.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.thelincolnianonline.com/2019/02/11/town-country-bank-trust-co-dba-first-bankers-trust-co-acquires-43992-shares-of-abbvie-inc-abbv.html.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C.
Further Reading: How to Calculate Compound Annual Growth Rate (CAGR)
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.